812P - Prognostic significance of early tumor shrinkage under second-line targeted therapy for metastatic renal cell carcinoma: a retrospective multiinsti...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Anti-Cancer Agents & Biologic Therapy
Renal Cell Cancer
Presenter Hideaki Miyake
Citation Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373
Authors H. Miyake1, S. Ozono1, M. Fujisawa2
  • 1Urology, Hamamatsu University School of Medicine, 431-3192 - Hamamatsu/JP
  • 2Urology, Kobe University Graduate School of Medicine, 650-0017 - Kobe/JP

Abstract

Background

The prognostic significance of early tumor shrinkage (ETS) under second-line targeted therapy for metastatic renal cell carcinoma (mRCC) has not been fully documented. The objective of this study was to evaluate the impact of ETS induced by a second-line targeted agent on overall survival (OS) in mRCC patients.

Methods

This study retrospectively included 271 consecutive Japanese patients with mRCC who received second-line targeted therapy for at least 3 months. ETS was defined as the degree of tumor shrinkage at the first post-baseline radiological evaluation conducted 4 – 8 weeks after initiating second-line targeted therapy.

Results

Of these 271 patients, 26 had ETS from -100 to -50%, 70 from -49 to -25%, 84 from -24 to 0%, and the remaining 91 failed to achieve a reduction in the tumor size. The median OS following the initiation of second-line targeted therapy stratified according to ETS was 45.8, 30.9, 22.1 and 14.2 months, respectively. Univariate analysis identified prior nephrectomy, the Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification, C-reactive protein (CRP) level, number of metastatic organs, sarcomatoid feature, introduced second-line agent and ETS induced by a second-line agent as parameters significantly associated with OS, of which, only the MSKCC classification, CRP level and ETS appeared to have independent impacts on OS on multivariate analysis.

Conclusions

ETS at the first post-baseline assessment under treatment with a second-line targeted agent could serve as a useful parameter with an independent impact on OS in mRCC patients receiving second-line targeted therapy. Therefore, it is highly recommended to select second-line targeted agents that make it possible to induce prompt tumor remission to further improve the prognosis of mRCCpatients following the failure of first-line targeted therapy.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Japanese Society of the Promotion of Science

Disclosure

All authors have declared no conflicts of interest.